NYSE: WST

West Pharmaceutical Services (WST) Stock Analysis & Forecast

Nov 13 close

$416.42+5.12 (+1.2%)

Gekko Brief

AI summaryNov 13 close

West Pharmaceutical Services' week centers on strong Q3 2026 results and a raised outlook: sales of $874.5 million and net income of $214 million led management to lift full-year net sales guidance to $3.41 billion to $3.42 billion and diluted EPS to $9.31 to $9.41, alongside share repurchases. This built on the prior quarter's beat, where adjusted EPS of $2.37 topped estimates of $2.08. Alongside the raised outlook, commentary has turned to valuation, with separate pieces questioning whether the stock's 54.7% one-year gain is justified by cash flow, with one view suggesting shares could be roughly 29% overvalued on a discounted cash flow basis.

WST closed at $416.42, up 1.2%, sitting above both its 50-day average of $380.17 and 200-day average of $321.39, with the shorter average above the longer one. The GekkoIndex reads 51.8, placing it in the Neutral zone. Against this, Gekko Fair Value stands at $361.23, putting the current price 15.3% above that level.

The next earnings date falls on 11 February 2027, 89 days out and beyond a typical 20-day holding window. No insider, Congress or unusual options activity appears in their respective windows, and a recent filing shows Candriam S.C.A. increasing its stake by 3.3%. Seasonally, the next 20 trading days have averaged a 1.9% gain over 5 years, rising in 4 of them. Analyst coverage from 6 firms is unanimously rated buy, with a consensus target of 471.

Written by AI from the Nov 13, 2026 close and checked automatically against the figures on this page.

West Pharmaceutical Services price vs fair value

$416.42$363.06Nov ’25May ’26Nov ’26
Close $416.42200-day averageGekko Fair Value $363.06

West Pharmaceutical Services quick facts

Market cap
$29.01B
P/E ratio
46.2
Forward P/E
41.5
EPS, TTM
$8.91
Revenue, TTM
$3.40B
Profit margin
18.8%
Dividend yield
0.21%
Beta
1.14
Volume
473,620 avg 759,426
1-year return
+52.1%
Typical daily move
±3%
Typical 20-day move
±5.5%
50-day average
$380.17
200-day average
$321.39
Next earnings
Feb 11 before open
Shares outstanding
69.66M
52-week range
$223.83$438.27

West Pharmaceutical Services swing-trade checklist

West Pharmaceutical Services scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $416.42 is above the 50-day ($380.17) and 200-day ($321.39) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    51.8, Neutral

    Reading 51.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    14.7% above

    Price is 14.7% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +1.9% on average

    From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

West Pharmaceutical Services stock chart and price history

West Pharmaceutical Services closed at $416.42 on Nov 13, 2026, +52.1% over the past year, inside a 52-week range of $223.83 to $438.27.

Close50-day average200-day averageVolume
West Pharmaceutical Services share price, past year, with 50-day and 200-day moving averages and volume$250$300$350$400DecJan 2026FebMarAprMayJunJulAugSepOctNov416.42

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+8.7%
3 months
+20.1%
6 months
+37.5%
1 year
+52.1%
The full WST chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open WST in Gekko

Follow West Pharmaceutical Services through every session

Put WST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track WST in GekkoFree for 7 days. No credit card required.

About West Pharmaceutical Services

West Pharmaceutical Services designs, manufactures, and distributes components used to package and deliver injectable medicines and other healthcare products. It is best known for parts such as stoppers, seals, and syringe and cartridge components that protect and administer injectable drugs, along with devices that support mixing, reconstitution, and self-injection.

The company organizes its work into two units. Its Proprietary Products business supplies packaging components, drug containment materials, self-injection devices, and support services such as lab analysis, packaging assistance, engineering, regulatory help, and technical support, mainly for makers of biologic, generic, and other pharmaceutical products. Its Contract-Manufactured Products business designs and assembles devices for surgical, diagnostic, ophthalmic, and drug delivery use, as well as consumer items, serving pharmaceutical, diagnostic, and medical device manufacturers. Products reach buyers worldwide through its own sales force, distribution network, and outside sales agents and distributors, with operations across the Americas, Europe, the Middle East, Africa, and Asia Pacific.

West Pharmaceutical Services was founded in 1923 and is headquartered in Exton, Pennsylvania. Its shares are listed on the NYSE under the ticker WST.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
westpharma.com

West Pharmaceutical Services GekkoIndex: the smart money zone

West Pharmaceutical Services’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.8, in the Neutral zone, down 0.5 points over five sessions.

010051.8Neutral

Down 0.5 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying35+2.4%+3.9%+4.4%+2.9%
Accumulation205−0.1%+0.1%0.0%+1.6%
Neutral (current zone)418+0.5%+0.6%+1.0%+0.8%
Distribution41−1.8%−1.5%−2.8%+3.4%
Selling3Too few readings yet

Average WST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the WST price, zone by zone.Track WST in Gekko

Is West Pharmaceutical Services stock overvalued? Gekko Fair Value

West Pharmaceutical Services trades 14.7% above Gekko Fair Value of $363.06, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what West Pharmaceutical Services shares are worth, recalculated every trading day.

$363.06

Gekko Fair Value, Nov 14, 2026

14.7% Overvalued

At the end of Aug 2026 the price was 26.9% above the estimate.

Gekko Fair ValueShare price, month end
$363$416Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open WST in Gekko

West Pharmaceutical Services insider and Congress trading

No open-market insider purchases were filed for West Pharmaceutical Services, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for WST in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every WST insider filing, plotted on the chart in Gekko.Open WST in Gekko

Congress trades last 90 days

No trades in WST were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for WST, plotted on the chart in Gekko.Open WST in Gekko

Buybacks

West Pharmaceutical Services has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$231.0M
As a share of market cap
0.80%
Trailing four quarters
$826.4M

From company filings.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds WST.

0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

West Pharmaceutical Services earnings: next date and track record

West Pharmaceutical Services reports on Feb 11, 2027, before the open (88 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±11%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+7.5%Oct ’24−33.4%Feb ’25−1.7%Apr ’25+15.9%Jul ’25+7.4%Oct ’25+1.8%Feb ’26+11.6%Apr ’26−8.4%Jul ’26

Last earnings call, Jul 23, 2026 AI summary

What they said
West Pharmaceutical Services reported a strong Q2 2026: revenues of $872 million, organic revenue growth of ~13% and adjusted EPS of $2.37 (up 29% y/y). Management cited execution against strategy and operational improvements (notably recovery actions following a cyber incident) as key drivers. Proprietary Products (particularly HVP Components and Biologics) were the primary growth engines; HVP Components represented ~49% of revenues and grew strongly both in GLP-1 and non-GLP-1 areas. Management raised full-year guidance for organic revenue growth to 10%–11% and adjusted EPS to $8.85–$9.05. Key strategic drivers discussed were Biologics/biosimilars, GLP-1s, Annex 1-driven HVP upgrades, and continued expansion in Delivery Devices (including SmartDose 3.5 and SelfDose). Management expressed confidence in multi-year opportunities (Annex 1, geographic expansion in APAC, GLP-1 biosimilars), while noting some near-term conservatism in the back half due to timing/ramps (West Vantage, Dublin) and the need to take a prudent quarter-by-quarter approach.
Guidance
Raised full year 2026 guidance: organic revenue growth to 10%–11%; adjusted EPS range $8.85 to $9.05. Additional commentary: GLP-1 HVP Components expected to continue double-digit growth and high-teens for GLP-1s for the full year; Proprietary Products mid/low double-digit (non-GLP HVP high teens). West Vantage drug handling revenue expected ~$20 million in 2026 (back-half loaded).
Risks flagged
Cyber incident impacts and recovery/timing risk; capacity and ramp risks (Dublin ramping, West Vantage throughput timing); near-term conservatism in guidance which may reflect execution/timing uncertainty; SmartDose integration/divestiture and its previous dilutive margin impact; commodity and energy cost volatility (and related price pass-through uncertainty); regulatory and market adoption timing (e.g., Annex 1 spillover, Medicare/market ramps for GLP-1s).
ReportedEPSSurpriseRevenueSurpriseMove
Jul 23, 2026$2.37
est $2.08
+13.9%$872.3M
est $840.0M
+3.8%−8.4%
Apr 23, 2026$2.13
est $1.68
+27.1%$844.9M
est $780.3M
+8.3%+11.6%
Feb 12, 2026$2.04
est $1.83
+11.5%$805.0M
est $794.9M
+1.3%+1.8%
Oct 23, 2025$1.96
est $1.68
+16.7%$804.3M
est $785.7M
+2.4%+7.4%
Jul 24, 2025$1.84
est $1.54
+19.5%$766.2M
est $726.1M
+5.5%+15.9%
Apr 24, 2025$1.45
est $1.26
+15.1%$698.0M
est $713.0M
−2.1%−1.7%
Feb 13, 2025$1.82
est $1.71
+6.4%$748.8M
est $740.5M
+1.1%−33.4%
Oct 24, 2024$1.85
est $1.50
+23.3%$746.9M
est $709.6M
+5.3%+7.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

West Pharmaceutical Services stock forecast and analyst price targets

Analysts’ average 12-month price target for West Pharmaceutical Services is $471.00, +13.1% from the last close, from 6 firms rating the stock in the last 90 days.

$471.00consensus 12-month target, +13.1% from the last close
Low $400High $500
Buy6
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 30TD CowenBuy, maintained$500+20.1%
Oct 30BarclaysBuy, maintained$500+20.1%
Oct 30CitiBuy, reiterated$494+18.6%
Oct 30UBSBuy, maintained$495+18.9%
Oct 30Evercore ISIBuy, maintained$480+15.3%
+1.0%average 20-day move after past Neutral readings
+1.9%average move over the next 20 trading days in the last 5 years
±3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

West Pharmaceutical Services seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, West Pharmaceutical Services averaged +1.9% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

+1.5%2021+4.0%2022+3.5%2023−2.4%2024+4.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.5%3 of 5
Next 10 trading days−0.7%3 of 5
Next 15 trading days−1.4%2 of 5
Next 20 trading days+1.9%4 of 5
Next 30 trading days+2.2%3 of 5

For scale, WST’s typical 20-trading-day move in either direction is about 5.5%.

West Pharmaceutical Services market cap and key statistics

West Pharmaceutical Services’s market cap is $29.01B, with a P/E ratio of 46.2 and revenue of $3.40B over the last twelve months.

Valuation

Market cap
$29.01B
P/E ratio
46.2
Forward P/E
41.5
EPS, TTM
$8.91
Gekko Fair Value
$363.06

Trading

Volume
473,620
Avg volume, 20 days
759,426
52-week high
$438.27
52-week low
$223.83
Shares outstanding
69.66M

Financials

Revenue, TTM
$3.40B
Profit margin
18.8%
Return on equity
21.2%
Quarterly earnings growth, YoY
+57.3%

Risk and income

Beta
1.14
Typical daily move
±3%
Typical 20-day move
±5.5%
Dividend yield
0.21%

West Pharmaceutical Services stock news this week

Coverage of West Pharmaceutical Services this week reads positive: 2 positive, 1 neutral and 1 negative headlines.

News sentiment positive

West Pharmaceutical Services peers

West Pharmaceutical Services’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

West Pharmaceutical Services stock FAQ

What is West Pharmaceutical Services’s market cap?

West Pharmaceutical Services’s market cap is $29.01B at the Nov 13, 2026 close of $416.42, with 69.66M shares outstanding. The shares trade on a P/E ratio of 46.2.

What is the West Pharmaceutical Services stock forecast?

The consensus analyst 12-month price target for West Pharmaceutical Services is $471.00, +13.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is West Pharmaceutical Services stock overvalued or undervalued?

On Gekko’s estimate West Pharmaceutical Services is overvalued: the Nov 13, 2026 close of $416.42 is 14.7% above Gekko Fair Value of $363.06. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does West Pharmaceutical Services report earnings next?

West Pharmaceutical Services is expected to report on Feb 11, 2027, before the market opens (88 days away). Analysts expect earnings of $2.27 per share on revenue of $825.2M. West Pharmaceutical Services beat the earnings estimate in 8 of its last 8 reports, moving 11% on average across the report.

What is West Pharmaceutical Services’s 52-week high and low?

West Pharmaceutical Services’s 52-week high is $438.27 and its 52-week low is $223.83; it closed at $416.42 on Nov 13, 2026, +52.1% over the past year. Over the last five years the shares peaked at $475.00 on Dec 27, 2021.

Is West Pharmaceutical Services stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See West Pharmaceutical Services the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.